Intravenous administration of cibenzoline significantly reduced left ventricular end-diastolic pressure from 22 to 14 mmHg in patients with hypertrophic obstructive cardiomyopathy.
Observational (n=16)
No
Does intravenous cibenzoline improve left ventricular diastolic pressures and transmitral Doppler flow profiles in patients with hypertrophic cardiomyopathy?
Intravenous cibenzoline acutely reduces left ventricular diastolic pressures and improves transmitral Doppler flow profiles in patients with both obstructive and nonobstructive hypertrophic cardiomyopathy.
Absolute Event Rate: 14% vs 22%
p-value: p=0.0106
BACKGROUND: Cibenzoline is able to improve left ventricular (LV) diastolic dysfunction in patients with hypertrophic cardiomyopathy (HCM), but the exact mechanism remains to be determined. METHODS AND RESULTS: The present study was designed to elucidate the effect of intravenous administration of 1.4 mg/kg of cibenzoline on aortic and LV pressures, and transmitral Doppler flow pattern in 7 patients with hypertrophic obstructive cardiomyopathy (HOCM) and 9 patients with hypertrophic nonobstructive cardiomyopathy (HNCM). Before and at the end of the administration, aortic and LV pressures, LV pressure gradient (LVPG) and transmitral Doppler velocity profiles were examined. After the administration of cibenzoline, LV minimal and end-diastolic pressures decreased from 9+/-4 mmHg to 1+/-5 mmHg (p=0.0049) and from 22+/-7 mmHg to 14+/-5 mmHg (p=0.0106) in patients with HOCM, and from 9+/-5 mmHg to 5+/-3 mmHg (p=0.0036) and from 20+/-6 mmHg to 14+/-3 mmHg (p=0.0033) in patients with HNCM. LVPG decreased in all patients with HOCM. E-wave velocity increased, A-wave velocity decreased, and thus the E/A ratio increased from 0.77+/-0.29 to 1.20+/-0.48 (p=0.0004). CONCLUSIONS: Reduction of LV diastolic pressures by intravenous administration of cibenzoline may be related to an improvement in the E/A ratio in patients with HCM.
Hamada et al. (Mon,) conducted a observational in Hypertrophic cardiomyopathy (HCM) (n=16). Cibenzoline vs. Baseline (before administration) was evaluated on Left ventricular end-diastolic pressure (LVEDP) in HOCM patients (p=0.0106). Intravenous administration of cibenzoline significantly reduced left ventricular end-diastolic pressure from 22 to 14 mmHg in patients with hypertrophic obstructive cardiomyopathy.